ArticleScientific reports2025
Investigating a novel β-glucan source to enhance disease resistance in Pacific white shrimp (Penaeus vannamei).
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Effects of a Mixed Biomass of Thalassiosira weissflogii and Chaetoceros calcitrans as a Functional Feed Additive for Pacific White Shrimp (Penaeus vannamei).Marine biotechnology (New York, N.Y.) · 2026Article
- Epigenetic Landscape of H3K27ac, H3K27me3, H3K4me1, and H3K4me3 Marks in Channel Catfish Following Βeta Glucan Exposure.International journal of molecular sciences · 2026Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
β-glucans supplements are known for enhancing disease resistance and performance in shrimp aquaculture, but their effectiveness depends on their source and structure. This study investigated a novel β-glucan derived from the insect fungus Ophiocordyceps dipterigena BCC 2073 as a potential feed additive for Pacific white shrimp (Penaeus vannamei). To determine its feasibility, juvenile shrimps were fed diets supplemented with 0%, 0.1%, and 0.4% β-glucan oligosaccharide for 30 days prior to their performance evaluation. The groups with β-glucan supplementation showed improved immune levels and significantly higher survival rates (p-value < 0.05) when exposed to the pathogen Vibrio harveyi. Transcriptome, microbiome, and metabolome were employed to understand mechanisms of β-glucan supplement. The feed additive altered the expression of host genes linked to immunity, inflammation, and intestinal barrier function. Moreover, Vibrio spp. and Pseudoalteromonas spp. abundances were significantly modulated (p-value < 0.05) with specific Vibrio clades responding differently depending on the β-glucan concentration. Metabolomic analysis revealed immune-supporting metabolites such as hydroquinone and nicotinic acid, potentially promoting homeostasis, consistent with the observed gene expression profiles. This study highlights the potential of O. dipterigena BCC 2073 β-glucan as a novel feed additive to improve disease resistance and shrimp health.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.